- Home
- CELC vs VERA Comparison
CELC vs VERA Comparison
Compare CELC & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELC | VERA |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CELC | VERA |
|---|---|---|
| Price | $104.79 | $41.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $100.13 | $76.60 |
| AVG Volume (30 Days) | 672.2K | ★ 859.6K |
| Earning Date | 02-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.58 | $18.53 |
| 52 Week High | $120.32 | $56.05 |
Technical Indicators
Market Signals| Indicator | CELC | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 48.10 | 39.81 |
| Support Level | $103.20 | $41.76 |
| Resistance Level | $109.75 | $44.66 |
| Average True Range (ATR) | 5.73 | 2.14 |
| MACD | -0.53 | -0.18 |
| Stochastic Oscillator | 47.16 | 9.80 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.